Email Updates

You are here


Media Coverage

  • Twenty years ago, the world faced a devastating pandemic that was spreading rapidly around the world. Then, 5 million people were being infected with HIV and 3 million were dying from AIDS each year. In 2020, an estimated 1.5 million people were infected with HIV, and AIDS killed an estimated 680,000 people. This progress did more than save lives; it built the public health foundations that many countries now use to confront the COVID-19 pandemic.

    January 28, 2022
    The Hill
  • Today, HIV can be kept under control, but for most people, there is no cure because the virus can become dormant so HIV medicines have no effect. That could change in future, now progress has been made in waking up dormant viruses. People with HIV can take antiviral medicines that stop the virus from reproducing, giving them nearly normal lifespans. But HIV inserts copies of its genetic material into human immune cells, which then become dormant.

    January 26, 2022
    New Scientist
  • Clinical trials are not often diverse — meaning medical solutions often don’t account for the needs of a wide range of communities. A 2020 global analysis of participation in clinical trials found that 76 percent of participants were white, 11 percent Asian, and 7 percent Black.

    January 26, 2022
  • Over two decades, more than 80 percent of transgender women living with HIV had ever received HIV care, more than 70 percent were currently in care and more than 60 percent had an undetectable viral load, according to a systematic review and meta-analysis published in the journal AIDS. There were not enough data on trans men to do a similar analysis for that population.

    January 25, 2022
  • The pandemic has brought back painful memories for Eric Sawyer, a founding member of the AIDS advocacy group ACT UP, who also lost his partner to the disease. "The misinformation, the hysteria, the spread of just absolute lies (and) the attempts by individuals to address it being part of the problem," said Sawyer, who also worked with the UN's HIV/AIDS program.

    January 25, 2022
    France 24
  • In December, the International Partnership for Microbicides (IPM) pulled its application for FDA approval for the pre-exposure prophylaxis (PrEP) ring. Now, one year after the World Health Organization recommended the ring for member nations, there appears to be no path forward in the United States for either the dapivirine-only ring, or an approach that would change the game: a vaginal ring that supplies both contraception and HIV prevention.

    January 24, 2022
  • London’s 56 Dean Street, the largest sexual health clinic in Europe, has just reported its latest data on new HIV diagnoses. They show that while the number of new diagnoses among its users continued to fall in 2020, the proportion who had been recently taking pre-exposure prophylaxis (PrEP) considerably increased.

    January 24, 2022
  • We must make an effort to understand what drives people to behave in certain ways, why certain behaviours perceived as risky are important to them, and meet them where they are by acknowledging and respecting their value systems. Social, affective and cultural factors are at play. Desire, pleasure, the pull of intimacy, the need for proximity and physical contact are important in determining what people ultimately do.

    January 21, 2022
    The Guardian
  • Researchers have looked at the social and economic benefits of starting people with HIV on immediate treatment. This is called ‘test and treat’. The alternative is to start people on treatment when HIV advances to a certain level. But test and treat is better because it enables people with HIV to maintain their health. Because it helps people become virally suppressed it also reduces HIV transmission.

    January 21, 2022
  • In sub-Saharan Africa, adolescent girls and young women (AGYW, aged 15–24 years) bear a disproportionate burden of HIV infection, as they are more than twice as likely to acquire HIV than their male counterparts. Fortunately, oral pre-exposure prophylaxis (PrEP) is a self-initiated option to reduce AGYW's HIV risk; however, oral PrEP uptake remains low among AYGW. Perceived stigma and low risk perception are some reasons that preclude AGYW from seeking out oral PrEP.

    January 20, 2022

Published Research